Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tinidazole is a synthetic antiprotozoal and antibacterial agent belonging to the nitroimidazole class. It is used primarily to treat protozoan infections such as trichomoniasis (a sexually transmitted infection), giardiasis (intestinal infection), and amebiasis (intestinal and extra-intestinal). It is also indicated for bacterial vaginosis in adult women. The drug acts as a prodrug; its nitro group is reduced by microbial electron transport proteins (such as ferredoxin) within susceptible organisms. This reduction generates free nitro radicals that bind covalently to DNA and other macromolecules in the pathogen—causing DNA damage and cell death. Tinidazole was developed in 1972 and remains widely used globally for anaerobic amoebic and bacterial infections[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tinidazole.